about
Genetically modified hematopoietic stem cell transplantation for HIV-1-infected patients: can we achieve a cure?Aptamers in diagnostics and treatment of viral infectionsGene therapy strategies for HIV/AIDS: preclinical modeling in humanized miceSimultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth.How to train your dragon: targeted delivery of microRNA to cancer cells in vivo.Stabilization of RNA hairpins using non-nucleotide linkers and circularization.Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein BiomarkersCD4 aptamer-RORγt shRNA chimera inhibits IL-17 synthesis by human CD4(+) T cells.Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicineEvidence for multiple distinct interactions between hepatitis B virus P protein and its cognate RNA encapsidation signal during initiation of reverse transcription.New strategies for evaluation and analysis of SELEX experimentsCell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cellsAptamers as a novel tool for diagnostics and therapy.Aptamers: current challenges and future prospects.Cell-targeting aptamers act as intracellular delivery vehicles.High throughput sequencing analysis of RNA libraries reveals the influences of initial library and PCR methods on SELEX efficiency.EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer ModelSelection of 2'-deoxy-2'-fluoroarabinonucleotide (FANA) aptamers that bind HIV-1 reverse transcriptase with picomolar affinityCo-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancerA review of therapeutic aptamer conjugates with emphasis on new approaches.A novel platform to enable inhaled naked RNAi medicine for lung cancer.Aptamer-PEG-modified Fe3O4@Mn as a novel T1- and T2- dual-model MRI contrast agent targeting hypoxia-induced cancer stem cells.NADPH oxidase in brain injury and neurodegenerative disordersAptamers: multifunctional molecules for biomedical research.Advances in siRNA delivery to T-cells: potential clinical applications for inflammatory disease, cancer and infection.Current progress on aptamer-targeted oligonucleotide therapeutics.Oligonucleotide aptamers: new tools for targeted cancer therapy.An aptamer intrinsically comprising 5-fluoro-2'-deoxyuridine for targeted chemotherapy.Aptamers and their applications in nanomedicine.Geroprotectors: A Unified Concept and Screening Approaches.Nanomaterial coatings applied on stent surfaces.Advancement of the Emerging Field of RNA Nanotechnology.Aptamer-Mediated Codelivery of Doxorubicin and NF-κB Decoy Enhances Chemosensitivity of Pancreatic Tumor Cells.Methods for Evaluating Cell-Specific, Cell-Internalizing RNA Aptamers.RNA self-processing: formation of cyclic species and concatemers from a small engineered RNA.Using Planar Phi29 pRNA Three-Way Junction to Control Size and Shape of RNA Nanoparticles for Biodistribution Profiling in Mice.An Albumin-Oligonucleotide Assembly for Potential Combinatorial Drug Delivery and Half-Life Extension Applications.Cancer therapy using oligonucleotide-based STAT3 inhibitors: will they deliver?RNA versatility, flexibility, and thermostability for practice in RNA nanotechnology and biomedical applications.Selection and Identification of Skeletal-Muscle-Targeted RNA Aptamers.
P2860
Q26995220-35B859DE-6527-4443-969D-9D8298F880A5Q27014527-D2A2A7BA-0DDA-427F-92EC-B73D9F7465F2Q27022347-C6A66858-2C5F-48C4-986D-EF1208420034Q33588273-674E6729-6214-4476-ACE8-169826790A32Q33724285-6F9F7DA3-003A-4CDA-8914-26D7C2A169CDQ33741196-7FECC162-977C-4F8E-A28C-5028E12AA249Q33832781-857AA486-BD25-4C66-9948-4A8ABA131E87Q34435503-A14A3386-894E-467A-AFF8-ECCBFAAF0DA6Q34698624-875BFE31-AC37-48EF-9B54-EBE6AD8BF41BQ34974070-47F81298-9429-4B29-91A3-CFFCD33028D8Q35159247-1F10A3EA-8598-4BB4-83A8-109DDCDA19AEQ35335653-C8686C45-7D5A-43E7-8624-BD15B7536EEFQ35552275-F716DE75-51A9-41A2-BABD-7E823DCC0CFFQ35859041-B48C3892-8DC1-41DB-AA84-F855B332B245Q36062913-0615A548-CB42-438B-95A9-88A75481F383Q36139325-74CBD736-0D19-4D5B-B2BC-BA83234B5654Q36352817-3F092B65-9A6A-4713-BEEC-0730557A01D5Q36575322-AE02A291-FE3D-4243-94C5-BCD27C0BA940Q37125328-7083807F-65FC-4C21-AA8D-6C6CA7FBF639Q37277378-152E8F12-A936-4A3B-952C-0026F4A52EC9Q37338963-EF11B06A-882C-489D-BB81-D2291DAB5DA8Q37504779-07ACAA18-920A-43C2-92BC-11CBD1E6D34DQ37589114-8A7DDD69-DFC0-448C-9D9B-6AFAFBCE00C2Q38138814-27CE91D9-B039-4BEA-8162-AE54D11A8250Q38144256-54D7B6BF-2849-48F0-AB7E-BB5C96F36B21Q38168595-99175489-F695-44F5-A1F9-CCBCD9568BBEQ38237132-21B54A85-6916-4FF4-8D0A-5C57772240C9Q38304827-2C96499B-FA7B-48A6-8AB1-256D85863701Q38353973-07ED46CF-53C4-4836-AEEC-85FF596DEF5BQ38744592-4426474A-14C5-417E-96E8-18A409714B0EQ38816692-9DDA0822-449A-4B77-A21B-6DB90DBBE9AFQ39065708-9E71AD48-2379-4257-94EC-523909923D67Q40174969-CD467332-6CD2-4B44-9FED-F09EFDA68439Q43075645-F04FF11B-831E-479C-AF9F-562C8B5B60AEQ44672368-A13BBA95-F58B-4E3F-9C15-95CF85B9EEE5Q47199019-06620BA5-4B8A-430B-9AD3-969692B4881DQ47288556-427801DD-5CE9-467B-85F4-5C93E9586E3BQ47605309-7C309D82-2461-4F20-A54A-D7E66446A869Q50144632-C898FA87-1114-4E71-A2B1-E4D531360C7EQ52676614-A3EDA822-F733-4174-BCB9-6015C0BF9C98
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Current progress of RNA aptamer-based therapeutics.
@ast
Current progress of RNA aptamer-based therapeutics.
@en
type
label
Current progress of RNA aptamer-based therapeutics.
@ast
Current progress of RNA aptamer-based therapeutics.
@en
prefLabel
Current progress of RNA aptamer-based therapeutics.
@ast
Current progress of RNA aptamer-based therapeutics.
@en
P2093
P2860
P356
P1476
Current progress of RNA aptamer-based therapeutics.
@en
P2093
Jiehua Zhou
John C Burnett
John J Rossi
Maggie L Bobbin
P2860
P356
10.3389/FGENE.2012.00234
P577
2012-11-02T00:00:00Z